{"success":true,"data":{"pressRelease":{"id":"23261","rtpr_id":"nPn5DrQ9Da","ticker":"MEDP","exchange":"NASDAQ","all_tickers":["MEDP"],"title":"MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After President Allegedly Oversaw Misleading Disclosures: Levi & Korsinsky","author":"PR Newswire","published_at":"2026-05-06T13:00:00.352Z","article_body":"MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After President Allegedly Oversaw Misleading Disclosures: Levi & Korsinsky\n\nPR Newswire\n\nNEW YORK, May 6, 2026\n\nExecutive Accountability: Jesse J. Geiger Named in Securities Action\n\nNEW YORK, May 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies\ninvestors that Jesse J. Geiger, President of Medpace Holdings Inc. (NASDAQ:\nMEDP), is named as a defendant in a securities class action covering purchases\nbetween April 22, 2025 and February 9, 2026. Find out if you qualify to\nrecover losses from the MEDP securities action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681714-18&h=2331915773&u=https%3A%2F%2Fzlk.com%2Fpslra-1%2Fmedpace-holdings-inc-lawsuit-submission-form-2%3Fprid%3D185515%26wire%3D4&a=Find+out+if+you+qualify+to+recover+losses+from+the+MEDP+securities+action)\n. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com\n(mailto:jlevi@levikorsinsky.com)  or (212) 363-7500.\n\n(https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.html)\n\nMedpace shares fell $84.30 per share, a decline of over 15.9%, after the\nCompany revealed a Q4 2025 book-to-bill ratio of just 1.04x against repeated\nguidance of 1.15x. The lead plaintiff deadline is June 8, 2026.\n\nJesse J. Geiger's Role During the Class Period\n\nAs President of Medpace, Geiger delivered quarterly financial results directly\nto investors and analysts throughout the Class Period. The complaint alleges\nthat on April 22, 2025 Geiger presented Q1 2025 revenue of $558.6 million and\nreporting a 0.9 net book-to-bill, while framing the Company's backlog\ntrajectory in optimistic terms. On October 23, 2025, Geiger reported Q3\nrevenue of $659.9 million and a 1.20 book-to-bill, reinforcing investor\nconfidence in the Company's growth trajectory.\n\nBy February 10, 2026, Geiger disclosed Q4 revenue of $708.5 million but a\nsharply disappointing 1.04 net book-to-bill, as net new business awards of\n$736.6 million failed to keep pace with the Company's own projections.\n\nWhat Geiger Allegedly Oversaw\n\nThe action contends that Geiger, as President, possessed the power and\nauthority to control the contents of Medpace's SEC filings, press releases,\nand analyst presentations. As named in the action, Geiger had access to\nmaterial non-public information about the Company's backlog cancellation\ntrends and the concentration of growth in the metabolic therapeutic area. The\ncomplaint charges that Geiger knew or recklessly disregarded that:\n\n * Backlog cancellations were accelerating, particularly in metabolic trials\n * The projected 1.15x book-to-bill ratio for the second half of fiscal 2025 was\nnot achievable given known cancellation trends\n * Revenue growth was disproportionately dependent on metabolic studies rather\nthan being \"broad-based\" as represented to investors\n * The pre-backlog pipeline's therapeutic concentration created material risk to\nforward bookings\n * Positive quarterly presentations omitted these adverse trends, leaving\ninvestors without material information\nGeiger's Certifications and Liability\n\nUnder Section 20(a) of the Securities Exchange Act of 1934, the complaint\nasserts that Geiger acted as a controlling person of Medpace by virtue of his\nposition, authority over public disclosures, and direct involvement in\nearnings presentations. The pleading asserts that Geiger received copies of\nthe Company's reports and press releases prior to issuance and had the ability\nand opportunity to prevent their issuance or cause them to be corrected.\n\n\"Individual officers who sign SEC certifications bear personal responsibility\nfor the accuracy of corporate disclosures. When executives present financial\nresults directly to the investing public, accountability follows,\" stated\nJoseph E. Levi, Esq.\n\nSpeak with an attorney about recovering damages in the Medpace action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681714-18&h=460911360&u=https%3A%2F%2Fzlk.com%2Fpslra-1%2Fmedpace-holdings-inc-lawsuit-submission-form-2%3Fprid%3D185515%26wire%3D4&a=Speak+with+an+attorney+about+recovering+damages+in+the+Medpace+action)\n or call (212) 363-7500.\n\nLEAD PLAINTIFF DEADLINE: June 8, 2026\n\nLevi & Korsinsky, LLP, Top 50 securities litigation firm (ISS, seven\nconsecutive years). Over 70 professionals. Hundreds of millions recovered for\ninvestors.\n\nFrequently Asked Questions About the MEDP Lawsuit\n\nQ: Who are the defendants named in the MEDP lawsuit?A: The complaint names\nMedpace Holdings Inc. and individual defendants including CEO August James\nTroendle, President Jesse J. Geiger, and CFO Kevin M. Brady, senior executives\nwho made public statements, signed SEC filings, and certified financial\ndisclosures under Sarbanes-Oxley.\n\nQ: Who is eligible to join the MEDP investor lawsuit?A: Investors who\npurchased MEDP stock or securities between April 22, 2025 and February 9, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses, not on whether you still hold the shares.\n\nQ: What does it cost me to participate?A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What is a lead plaintiff and why does it matter?A: A lead plaintiff is the\ninvestor appointed by the court to represent the entire class. Lead plaintiffs\nare typically investors with the largest documented losses. Being appointed\ndoes not increase individual recovery but gives direct oversight of how the\ncase is run.\n\nQ: What if I already sold my MEDP shares -- can I still recover losses?A: Yes.\nEligibility is based on when you purchased, not whether you still hold them.\nInvestors who bought during the class period and sold at a loss may still\nparticipate.\n\nQ: How long will the lawsuit take to resolve?A: Securities class actions\ntypically take two to four years from initial filing to resolution.\n\nCONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33\nWhitehall Street, 27th Floor New York, NY 10004 jlevi@levikorsinsky.com\n(mailto:jlevi@levikorsinsky.com)  Tel: (212) 363-7500 Fax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/medp-investor-alert-medpace-holdings-inc-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-president-allegedly-oversaw-misleading-disclosures-levi--korsinsky-302763822.html\n(https://www.prnewswire.com/news-releases/medp-investor-alert-medpace-holdings-inc-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-president-allegedly-oversaw-misleading-disclosures-levi--korsinsky-302763822.html)\n\nSOURCE Levi & Korsinsky, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5DrQ9Da","title":"MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After President Allegedly Oversaw Misleading Disclosures: Levi & Korsinsky","author":"PR Newswire","ticker":"MEDP","created":"2026-05-06T13:00:00.352Z","tickers":["MEDP"],"exchange":"NASDAQ","article_body":"MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After President Allegedly Oversaw Misleading Disclosures: Levi & Korsinsky\n\nPR Newswire\n\nNEW YORK, May 6, 2026\n\nExecutive Accountability: Jesse J. Geiger Named in Securities Action\n\nNEW YORK, May 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies\ninvestors that Jesse J. Geiger, President of Medpace Holdings Inc. (NASDAQ:\nMEDP), is named as a defendant in a securities class action covering purchases\nbetween April 22, 2025 and February 9, 2026. Find out if you qualify to\nrecover losses from the MEDP securities action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681714-18&h=2331915773&u=https%3A%2F%2Fzlk.com%2Fpslra-1%2Fmedpace-holdings-inc-lawsuit-submission-form-2%3Fprid%3D185515%26wire%3D4&a=Find+out+if+you+qualify+to+recover+losses+from+the+MEDP+securities+action)\n. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com\n(mailto:jlevi@levikorsinsky.com)  or (212) 363-7500.\n\n(https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.html)\n\nMedpace shares fell $84.30 per share, a decline of over 15.9%, after the\nCompany revealed a Q4 2025 book-to-bill ratio of just 1.04x against repeated\nguidance of 1.15x. The lead plaintiff deadline is June 8, 2026.\n\nJesse J. Geiger's Role During the Class Period\n\nAs President of Medpace, Geiger delivered quarterly financial results directly\nto investors and analysts throughout the Class Period. The complaint alleges\nthat on April 22, 2025 Geiger presented Q1 2025 revenue of $558.6 million and\nreporting a 0.9 net book-to-bill, while framing the Company's backlog\ntrajectory in optimistic terms. On October 23, 2025, Geiger reported Q3\nrevenue of $659.9 million and a 1.20 book-to-bill, reinforcing investor\nconfidence in the Company's growth trajectory.\n\nBy February 10, 2026, Geiger disclosed Q4 revenue of $708.5 million but a\nsharply disappointing 1.04 net book-to-bill, as net new business awards of\n$736.6 million failed to keep pace with the Company's own projections.\n\nWhat Geiger Allegedly Oversaw\n\nThe action contends that Geiger, as President, possessed the power and\nauthority to control the contents of Medpace's SEC filings, press releases,\nand analyst presentations. As named in the action, Geiger had access to\nmaterial non-public information about the Company's backlog cancellation\ntrends and the concentration of growth in the metabolic therapeutic area. The\ncomplaint charges that Geiger knew or recklessly disregarded that:\n\n * Backlog cancellations were accelerating, particularly in metabolic trials\n * The projected 1.15x book-to-bill ratio for the second half of fiscal 2025 was\nnot achievable given known cancellation trends\n * Revenue growth was disproportionately dependent on metabolic studies rather\nthan being \"broad-based\" as represented to investors\n * The pre-backlog pipeline's therapeutic concentration created material risk to\nforward bookings\n * Positive quarterly presentations omitted these adverse trends, leaving\ninvestors without material information\nGeiger's Certifications and Liability\n\nUnder Section 20(a) of the Securities Exchange Act of 1934, the complaint\nasserts that Geiger acted as a controlling person of Medpace by virtue of his\nposition, authority over public disclosures, and direct involvement in\nearnings presentations. The pleading asserts that Geiger received copies of\nthe Company's reports and press releases prior to issuance and had the ability\nand opportunity to prevent their issuance or cause them to be corrected.\n\n\"Individual officers who sign SEC certifications bear personal responsibility\nfor the accuracy of corporate disclosures. When executives present financial\nresults directly to the investing public, accountability follows,\" stated\nJoseph E. Levi, Esq.\n\nSpeak with an attorney about recovering damages in the Medpace action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681714-18&h=460911360&u=https%3A%2F%2Fzlk.com%2Fpslra-1%2Fmedpace-holdings-inc-lawsuit-submission-form-2%3Fprid%3D185515%26wire%3D4&a=Speak+with+an+attorney+about+recovering+damages+in+the+Medpace+action)\n or call (212) 363-7500.\n\nLEAD PLAINTIFF DEADLINE: June 8, 2026\n\nLevi & Korsinsky, LLP, Top 50 securities litigation firm (ISS, seven\nconsecutive years). Over 70 professionals. Hundreds of millions recovered for\ninvestors.\n\nFrequently Asked Questions About the MEDP Lawsuit\n\nQ: Who are the defendants named in the MEDP lawsuit?A: The complaint names\nMedpace Holdings Inc. and individual defendants including CEO August James\nTroendle, President Jesse J. Geiger, and CFO Kevin M. Brady, senior executives\nwho made public statements, signed SEC filings, and certified financial\ndisclosures under Sarbanes-Oxley.\n\nQ: Who is eligible to join the MEDP investor lawsuit?A: Investors who\npurchased MEDP stock or securities between April 22, 2025 and February 9, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses, not on whether you still hold the shares.\n\nQ: What does it cost me to participate?A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What is a lead plaintiff and why does it matter?A: A lead plaintiff is the\ninvestor appointed by the court to represent the entire class. Lead plaintiffs\nare typically investors with the largest documented losses. Being appointed\ndoes not increase individual recovery but gives direct oversight of how the\ncase is run.\n\nQ: What if I already sold my MEDP shares -- can I still recover losses?A: Yes.\nEligibility is based on when you purchased, not whether you still hold them.\nInvestors who bought during the class period and sold at a loss may still\nparticipate.\n\nQ: How long will the lawsuit take to resolve?A: Securities class actions\ntypically take two to four years from initial filing to resolution.\n\nCONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33\nWhitehall Street, 27th Floor New York, NY 10004 jlevi@levikorsinsky.com\n(mailto:jlevi@levikorsinsky.com)  Tel: (212) 363-7500 Fax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/medp-investor-alert-medpace-holdings-inc-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-president-allegedly-oversaw-misleading-disclosures-levi--korsinsky-302763822.html\n(https://www.prnewswire.com/news-releases/medp-investor-alert-medpace-holdings-inc-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-president-allegedly-oversaw-misleading-disclosures-levi--korsinsky-302763822.html)\n\nSOURCE Levi & Korsinsky, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-06T13:00:00.431892956Z","server_sent_at_ms":1778072400431},"received_at":"2026-05-06T13:00:00.485Z","source_url":null},"analysis":{"id":"17991","press_release_id":"23261","analysis_json":{"redFlags":[],"eventType":"legal_litigation","narrative":"Levi & Korsinsky, LLP issued a solicitation notice naming Medpace Holdings Inc. and its President, Jesse J. Geiger, in a securities class action covering purchases between April 22, 2025 and February 9, 2026.\n\nThe complaint alleges misleading disclosures regarding backlog cancellations and book-to-bill ratios, but this release is a law-firm marketing piece, not an issuer disclosure.\n\nThe firm is seeking a lead plaintiff with a deadline of June 8, 2026; participation is on a contingency basis.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Investors who purchased MEDP stock or securities between April 22, 2025 and February 9, 2026 and suffered financial losses may be eligible.","namedEntities":{"people":[{"name":"Jesse J. Geiger","role":"President of Medpace Holdings Inc."},{"name":"Joseph E. Levi","role":"Attorney at Levi & Korsinsky, LLP"},{"name":"August James Troendle","role":"CEO of Medpace Holdings Inc."},{"name":"Kevin M. Brady","role":"CFO of Medpace Holdings Inc."},{"name":"Ed Korsinsky","role":"Attorney at Levi & Korsinsky, LLP"}],"products":[],"companies":[{"name":"Medpace Holdings Inc.","ticker":"MEDP"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Levi & Korsinsky, LLP. No new disclosure from the issuer; no certified class, no settlement. This is a boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"MEDP"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky, LLP issued a solicitation notice naming Medpace Holdings Inc. and its President, Jesse J. Geiger, in a securities class action covering purchases between April 22, 2025 and February 9, 2026.\n\nThe complaint alleges misleading disclosures regarding backlog cancellations and book-to-bill ratios, but this release is a law-firm marketing piece, not an issuer disclosure.\n\nThe firm is seeking a lead plaintiff with a deadline of June 8, 2026; participation is on a contingency basis.","key_figures":{},"named_entities":{"people":[{"name":"Jesse J. Geiger","role":"President of Medpace Holdings Inc."},{"name":"Joseph E. Levi","role":"Attorney at Levi & Korsinsky, LLP"},{"name":"August James Troendle","role":"CEO of Medpace Holdings Inc."},{"name":"Kevin M. Brady","role":"CFO of Medpace Holdings Inc."},{"name":"Ed Korsinsky","role":"Attorney at Levi & Korsinsky, LLP"}],"products":[],"companies":[{"name":"Medpace Holdings Inc.","ticker":"MEDP"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-06T22:51:08.993Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":null,"modelName":"glm-4.7"}}